# US 2026/0092330 A1 · Analytical methods, kit and detection devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092330 A1
- Document ID: US20260092330A1
- Status: Published application
- Kind: A1
- Application number: 19/403,584
- Filed: 2025-11-28
- Published: 2026-04-02
- Earliest claimed: 2023-06-20
- Assignees: Kabushiki Kaisha Toshiba
- Applicants: Kabushiki Kaisha Toshiba
- Inventors: Takuya MIYAGAWA; Yoshitake SANO; Tomomi TAKAHASHI; Mitsuko ISHIHARA
- Web page: https://patentgrep.com/patent/US20260092330A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

According to one embodiment, analytical methods and kits are provided for determining the probability that a subject has breast cancer, pancreatic cancer, lung cancer, gastric cancer, or colorectal cancer. The analytical methods include quantifying a target miRNA selected from a group of target miRNAs in a sample derived from the subject to be analyzed.

## Claims

### Claim 1

An analytical method including:
quantifying a miRNA selected from the group consisting of hsa-miR-128-3p, hsa-miR-151a-3p, hsa-miR-143-3p, hsa-miR-4770, hsa-miR-1296-5p, hsa-miR-125a-5p, hsa-miR-409-3p, hsa-miR-99a-5p and hsa-miR-215-5p in a subject, and
determining a probability that the subject has breast cancer, pancreatic cancer, lung cancer, gastric cancer, or colorectal cancer.

### Claim 2 (depends on 1)

The method of claim 1, further comprising quantifying the miRNA in a control,
wherein the determination is made by comparing a quantitative value of the miRNA in the subject with a quantitative value of the miRNA in the control to determine a probability that the subject has breast cancer, pancreatic cancer, lung cancer, gastric cancer or colorectal cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the control is a healthy individual or an individual known to have at least one of breast, pancreatic, lung, gastric and colorectal cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the control is a healthy individual, and wherein the determination includes determining that the subject has breast, pancreatic, lung, gastric, or colorectal cancer when a quantitative value of hsa-miR-128-3p, hsa-miR-151a-3p, hsa-miR-4770, hsa-miR-125a-5p, hsa-miR-409-3p or hsa-miR-215-5p in the subject is less than a quantitative value in the control.

### Claim 5 (depends on 3)

The method of claim 3, wherein the control is a healthy individual, and wherein the determination includes determining that the subject has breast, pancreatic, lung, or gastric cancer when a quantitative value of hsa-miR-143-3p or hsa-miR-1296-5p in the subject is less than a quantitative value in the control.

### Claim 6 (depends on 3)

The method of claim 3, wherein the control is a healthy individual, and wherein the determination includes determining that the subject has breast, pancreatic, lung, or colorectal cancer when a quantitative value of hsa-miR-99a-5p in the subject is less than a quantitative value in the control.

### Claim 7 (depends on 3)

The method of claim 3, wherein the control is a colorectal cancer, and wherein the determination includes determining that the subject has breast, pancreatic, lung, or gastric cancer when a quantitative value of hsa-miR-128-3p, hsa-miR-151a-3p, hsa-miR-143-3p or hsa-miR-1296-5p in the subject is less than a quantitative value in the control.

### Claim 8 (depends on 3)

The method of claim 3, wherein the control is a colorectal cancer, and wherein the determination includes determining that the subject has breast, pancreatic or gastric cancer when a quantitative value of hsa-miR-4770 in the subject is less than a quantitative value in the control.

### Claim 9 (depends on 3)

The method of claim 3, wherein the control is a colorectal cancer, and wherein the determination includes determining that the subject has breast or pancreatic cancer when a quantitative value of hsa-miR-409-3p in the subject is less than a quantitative value in the control.

### Claim 10

An analytical method including:
quantifying a miRNA selected from the group consisting of hsa-miR-128-3p, hsa-miR-151a-3p, hsa-miR-143-3p, hsa-miR-4770, hsa-miR-125a-5p and hsa-miR-99a-5p in a subject, and
determining a probability that the subject has breast cancer.

### Claim 11 (depends on 10)

The method of claim 10, further comprising quantifying the miRNA in a control, wherein the determination is made by comparing a quantitative value of the miRNA in the subject with a quantitative value of the miRNA in the control to determine a probability that the subject has breast cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the control is an individual known to have at least one of pancreatic cancer, lung cancer, gastric cancer, or colorectal cancer.

### Claim 13 (depends on 11)

The method of claim 11, wherein the control has a lung or gastric cancer, and wherein the determination includes determining that the subject has breast cancer when a quantitative value of hsa-miR-128-3p in the subject is less than a quantitative value in the control.

### Claim 14 (depends on 11)

The method of claim 11, wherein the control has a lung cancer, and wherein the determination includes determining that the subject has breast cancer when a quantitative value of hsa-miR-151a-3p, hsa-miR-143-3p or hsa-miR-4770 in the subject is less than a quantitative value in the control.

### Claim 15 (depends on 11)

The method of claim 11, wherein the control has a colorectal, lung or gastric cancer, and wherein the determination includes determining that the subject has breast cancer when a quantitative value of hsa-miR-125a-5p in the subject is less than a quantitative value in the control.

### Claim 16 (depends on 11)

The method of claim 11, wherein the control has a gastric cancer, and wherein the determination includes determining that the subject has breast cancer when a quantitative value of hsa-miR-99a-5p in the subject is less than a quantitative value in the control.

### Claim 17

An analytical method including:
quantifying a miRNA selected from the group consisting of hsa-miR-126-3p, hsa-miR-326, hsa-miR-28-3p, hsa-miR-425-3p, hsa-miR-93-3p, hsa-miR-24-3p, hsa-miR-222-3p, hsa-miR-361-5p and hsa-miR-342-3p in a subject, and
determining a probability that the subject has breast, pancreatic or colorectal cancer.

### Claim 18 (depends on 17)

The method of claim 17, further comprising quantifying the miRNA in a control,
wherein the determination is made by comparing a quantitative value of the miRNA in the subject with a quantitative value of the miRNA in the control to determine a probability that the subject has breast, pancreatic or colorectal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the control is a healthy individual or an individual known to have at least one of breast, pancreatic or colorectal cancer.

### Claim 20 (depends on 19)

The method of claim 19, wherein the control is a healthy individual, and wherein the determination includes determining that the subject has breast, pancreatic or colorectal cancer when a quantitative value of hsa-miR-126-3p, hsa-miR-326, hsa-miR-28-3p, hsa-miR-425-3p, hsa-miR-93-3p, hsa-miR-24-3p, hsa-miR-222-3p or hsa-miR-361-5p in the subject is less than a quantitative value in the control.

### Claim 21 (depends on 19)

The method of claim 19, wherein the control is a healthy individual or breast cancer patient, and wherein the determination includes determining that the subject has pancreatic or colorectal cancer when a quantitative value of hsa-miR-342-3p in the subject is less than a quantitative value in the control.

### Claim 22

An analytical method, including:
quantifying a miRNA selected from the group consisting of hsa-miR-126-3p, hsa-miR-326, hsa-miR-28-3p, hsa-miR-425-3p, hsa-miR-93-3p, hsa-miR-24-3p, hsa-miR-222-3p, hsa-miR-361-5p, hsa-miR-342-3p and hsa-miR-10b-5p in a subject, and
determining a possibility that the subject has colorectal cancer.

### Claim 23 (depends on 22)

The method of claim 22, further comprising quantifying the miRNA in a control,
wherein the determination is made by comparing a quantitative value of the miRNA in the subject with a quantitative value of the miRNA in the control to determine a possibility that the subject has colorectal cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the control is an individual known to be at least one of a healthy individual, breast cancer patient or pancreatic cancer patient.

### Claim 25 (depends on 24)

The method of claim 24, wherein the control is a breast cancer patient or a pancreatic cancer patient, and wherein the determination includes determining that the subject has colorectal cancer when a quantitative value of each of hsa-miR-126-3p, hsa-miR-326, hsa-miR-28-3p, hsa-miR-425-3p, hsa-miR-93-3p, hsa-miR-24-3p, hsa-miR-222-3p or hsa-miR-361-5p in the subject is less than a quantitative value in the control.

### Claim 26 (depends on 24)

The method of claim 24, wherein the control is a pancreatic cancer patient, and wherein the determination includes determining that the subject has colorectal cancer when a quantitative value of hsa-miR-342-3p in the subject is less than a quantitative value in the control.

### Claim 27 (depends on 24)

The method of claim 24, wherein the control is a healthy individual, a breast cancer patient, or a pancreatic cancer patient, and wherein the determination includes determining that the subject has colorectal cancer when a e quantitative value of hsa-miR-10b-5p in the subject is less than a quantitative value in the control.

### Claim 28 (depends on 1)

The method of claim 1, wherein the quantification is performed using PCR, LAMP, or microarray.

### Claim 29 (depends on 1)

The method of claim 1, wherein the sample is serum or plasma.

### Claim 30 (depends on 2)

The method of claim 2, wherein the quantitative value of the miRNA in the subject and the quantitative value of the miRNA in the control are standardized by a standard miRNA commonly contained in the subject and the control.

### Claim 31 (depends on 30)

The method of claim 30, wherein the standard miRNA is hsa-miR-486-5p.

### Claim 32

A kit for determining the probability that the subject has breast, pancreatic, lung, gastric and colorectal cancer, comprising at least one nucleic acid set that specifically binds to a miRNA selected from the group consisting of hsa-miR-128-3p, hsa-miR-151a-3p, hsa-miR-143-3p, hsa-miR-4770, hsa-miR-1296-5p, hsa-miR-125a-5p, hsa-miR-409-3p, hsa-miR-99a-5p and hsa-miR-215-5p.

### Claim 33 (depends on 32)

The kit of claim 32, wherein the nucleic acid that specifically binds to the miRNA is a reverse transcription primer for reverse transcription of the miRNA, an elongation primer for elongation of the miRNA, an amplification primer set for amplifying the miRNA, or a nucleic acid probe for detecting the miRNA.
